The UK’s clinical trial landscape has begun to recover from post-Brexit problems including delays in the review of applications from sponsors and dwindling numbers of studies, prompting the Medicines and Healthcare products Regulatory Agency to consider options for avoiding similar disruptions in the future.
“We know that clinical trials have been through a difficult period